TELESCOPE INNOVATIONS CORP - TELIF STOCK NEWS

Telescope Innovations Corp. (TELIF) reports Q1 2024 financial results, with revenues of $1.50M and net income of $215,000, representing 300% growth over Q1 2023. The company attributes its strong performance to the momentum of its flagship product, DirectInject-LC, and the expansion of its technology and process development services with strategic partners in the pharmaceutical and chemical manufacturing sectors.

Telescope Innovations Corp. has filed a provisional patent application for a new technique to purify lithium carbonate, a critical mineral building block for lithium ion battery production. The new process produces battery-grade lithium carbonate in a single step, reducing the requirement for pre-processing of crude lithium brine feeds and refinement costs by up to 80%. The company aims to deploy its intellectual property through partnership and licensing models in the battery materials industry.

Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) reports financial results for the fiscal year ended August 31, 2023, with revenues of $2.82 M, representing a 375% increase over the previous fiscal year. The Company also experienced a net loss of $718,094 and total assets of $3,290,512. Telescope made significant strides in business development and investment in three strategic areas, including the launch of their Flagship product, DirectInjectTM-LC, which has been adopted by 13 of the top 20 pharmaceutical companies in the world. The Company also became the Provider-of-Choice for Self Driving Laboratories for major pharmaceutical manufacturers and invested in the development of intellectual property focused on high-value specialty materials. Telescope's COO, Jeffrey Sherman, expressed satisfaction with the adoption of their technology and aims to further grow strategic partnerships within the pharmaceutical and chemical manufacturing sector.

Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) has filed a provisional patent application for the production of lithium sulfide, a key precursor for next-generation solid-state batteries. The company's work with Standard Lithium Ltd. has led to the invention of a low-temperature method for generating lithium sulfide from brine-sourced lithium chemicals, potentially reducing production costs and enabling widespread deployment of solid-state batteries. Telescope's R&D technology, combining robotic automation, artificial intelligence, and online analytical platforms, has accelerated the discovery process and expanded the company's IP portfolio, positioning it among the 2% of Canadian SMEs to hold patents.

Telescope Innovations Corp. has signed a partnership with Mott Corporation to develop a novel robotic sampling probe for chemical analysis and purification. The sampling probe is designed for laboratory sample preparation and analysis markets, including for High-Performance Liquid Chromatography. If successful, the final product would be manufactured by Mott and commercialized exclusively by Telescope.

Telescope Innovations Corp.'s flagship product, Direct Inject Liquid Chromatography (DILCTM), has been rapidly adopted by 13 of the top 20 pharmaceutical companies in the world, leading to continued strong growth. Automation and data-rich analytical tools have become necessities in the pharmaceutical industry, enabling faster recovery from industrial upsets like the COVID-19 pandemic. DILCTM's sales revenues have supported the Company's technology development and growth. Telescope aims to be a partner-of-choice for lab automation tools in the chemical and biopharmaceutical sectors.

Telescope Innovations Corp. has been granted a Canadian patent for a scalable manufacturing process to produce pharmaceutically-relevant indole compounds. The patented process reduces manufacturing complexity and improves scalability for indole-based therapeutics. Telescope also patented a set of new molecules for preclinical development. The company's unique suite of analytical and automation technologies, including the DILC platform, played a crucial role in obtaining the patent.

Telescope Innovations Corp. grants 800,000 incentive stock options to directors.